We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus.
- Authors
Hadoux, Julien; Vignot, Stephane; De La Motte Rouge, Thibault
- Abstract
Metastatic renal cell carcinoma has harboured a poor prognosis for decades with immunotherapy being the only available therapy with high toxicity and modest effect. Dependance of renal cell carcinoma oncogenesis on the mTOR pathway has led to clinical development of temsirolimus in this setting. This sirolimus derivative has shown clinical efficacy in monotherapy for poor-risk renal cell carcinoma leading to an overall survival of 10.8 months in the pivotal phase III trial of this agent. Its specific adverse events consist of metabolic dysregulation (hyperlipemia, hyperglycemia), mucositis, rash and pneumonitis which can be severe and need careful monitoring and management. In this review, we will discuss of the clinical development of this molecule, its efficacy, its safety profile and future perspectives.
- Subjects
RENAL cell carcinoma; IMMUNOTHERAPY; CARCINOGENESIS; ADVERSE health care events; DRUG side effects; HYPERLIPIDEMIA; HYPERGLYCEMIA; PNEUMONIA; CANCER research; ONCOLOGY
- Publication
Clinical Medicine Insights: Oncology, 2010, Issue 4, p143
- ISSN
1179-5549
- Publication type
Article
- DOI
10.4137/CMO.S4482